Scalp, Eyebrow, and Eyelash Hair Regrowth with Continued Ritlecitinib Treatment Among Patients with Alopecia Areata Without Target Efficacy Response at Week 24: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

This post hoc analysis of the ALLEGRO phase 2b/3 study evaluated the efficacy of continued ritlecitinib treatment in patients with alopecia areata who did not meet target efficacy response at Week 24. The study included patients aged ≥12 years with ≥50% scalp hair loss, who received ritlecitinib 30 or 50 mg. Results showed that among those who did not respond by Week 24, 5-8% achieved a response by Week 28, increasing to 22-34% by Week 48. Similar improvements were observed for eyebrow and eyelash assessments. Ritlecitinib was well tolerated, with common adverse events including upper respiratory tract infection, nasopharyngitis, and headache. The study concludes that continued ritlecitinib treatment may lead to improved responses in patients who initially do not meet efficacy targets.